Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Study Details
Study Description
Brief Summary
This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
PRIMARY OBJECTIVE:
- To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) significantly prolongs overall survival (OS) versus (vs.) standard chemoradiotherapy with temozolomide in patients with newly diagnosed glioblastoma (GBM) with MGMT promoter methylation.
SECONDARY OBJECTIVES:
-
To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) significantly prolongs progression-free survival (PFS) vs. standard chemoradiotherapy with temozolomide in patients with newly diagnosed GBM with MGMT promoter methylation.
-
To compare the two different chemotherapy regimens on patient-reported outcomes (PROs), as measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed GBM with MGMT promoter methylation.
-
To determine if the regimen with the two alkylating agents temozolomide and lomustine with radiotherapy (RT) is associated with inferior short-term change in patient reported outcomes (PROs) as measured by MDASI-BT vs. standard chemoradiotherapy with temozolomide in patients with newly diagnosed GBM with MGMT promoter methylation.
-
To assess toxicity in the two different chemotherapy regimens.
EXPLORATORY OBJECTIVES:
- To assess the association between absolute lymphocyte counts and outcomes. II. To assess the association between CD4+ lymphocyte counts and outcomes. III. To compare the two different chemotherapy regimens in terms of long-term PROs as measured by MDASI-BT at years 1 and 2.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo radiation therapy 5 days per week and receive temozolomide orally (PO) once daily (QD) for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
ARM II: Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for year 1, every 4 months for year 2, and then every 6 months thereafter.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Arm I (radiation therapy, temozolomide) Patients undergo radiation therapy 5 days per week and receive temozolomide PO QD for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. |
Radiation: Photon Beam Radiation Therapy
Undergo radiation therapy
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
Other: Questionnaire Administration
Ancillary studies
Drug: Temozolomide
Given PO
Other Names:
|
Experimental: ARM II (radiation therapy, temozolomide, lomustine) Patients undergo radiation therapy 5 days per week for 6 weeks in the absence of disease progression or unacceptable toxicity. Patients also receive lomustine PO on day 1 and temozolomide PO QD on days 2-6. Treatment repeats every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. |
Drug: Lomustine
Given PO
Other Names:
Radiation: Photon Beam Radiation Therapy
Undergo radiation therapy
Other Names:
Other: Quality-of-Life Assessment
Ancillary studies
Other Names:
Other: Questionnaire Administration
Ancillary studies
Drug: Temozolomide
Given PO
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Overall Survival [From randomization to death due to any cause, assessed up to 4 years]
The Kaplan-Meier method will be used to estimate survival distribution for each treatment arm.
Secondary Outcome Measures
- Progression Free Survival (PFS) [From randomization to disease progression or death due to any cause, whichever occurs first, assessed up to 4 years]
Analysis will consist of estimation of the PFS distribution of each treatment arm via the Kaplan-Meier method and a stratified log-rank test. Additional analyses may consist of estimating the hazard ratio (HR) via the Cox proportional hazards model, accounting for other prognostic covariates (and evaluating whether the proportional hazards assumption holds or whether any treatment effect is notably time-varying), and evaluating for potential treatment by prognostic covariate interactions.
- Incidence of Adverse Events [Up to 4 years]
Adverse events (AEs) will be graded according to Common Terminology Criteria for Adverse Events version 5.0. Comprehensive summaries of all AEs by treatment arm will be generated and examined.
- Patient reported outcomes for Brain Tumors [Up to 4 years]
Measured by the MD Anderson Symptom Inventory - Brain Tumor (MDASI-BT) in patients with newly diagnosed glioblastoma with MGMT promoter methylation.
Other Outcome Measures
- Absolute lymphocyte counts [Up to 4 years]
Will assess the association between absolute lymphocyte counts and outcomes.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
STEP 1 REGISTRATION: No known IDH mutation. (If tested before step 1 registration, patients known to have IDH mutation in the tumor on local or other testing are ineligible and should not be registered)
-
STEP 1 REGISTRATION: Availability of formalin-fixed paraffin-embedded (FFPE) tumor tissue block and hematoxylin and eosin (H&E) stained slide to be sent for central pathology review for confirmation of histology and MGMT promoter methylation status. Note that tissue for central pathology review and central MGMT assessment must be received by the NYU Center for Biospecimen Research and Development (CBRD) on or before postoperative calendar day 23. If tissue cannot be received by postoperative calendar day 23, then patients may NOT enroll on this trial as central pathology review will not be complete in time for the patient to start treatment no later than 6 weeks following surgery. Results of central pathology review and central MGMT analysis will generally be conveyed to NRG Oncology within 10 business days of receipt of tissue. Note: In the event of an additional tumor resection(s), tissue must be received within 23 days of the most recent resection and the latest resection must have been performed within 30 days after the initial resection. Surgical resection is required; stereotactic biopsy alone is not allowed because it will not provide sufficient tissue for MGMT analysis
-
STEP 1 REGISTRATION: Contrast-enhanced brain MRI within 4 days after surgery
-
Magnetic resonance imaging (MRI) with Axial T2 weighted FLAIR or T2 TSE/FSE and 3D contrast-enhanced T1 sequences are required.
-
3-dimensional (3D) pre contrast-enhanced T1 sequences are strongly suggested
-
STEP 1 REGISTRATION: Willing to use highly effective method of contraception for participants of childbearing potential (participants who may become pregnant or who may impregnate a partner) during therapy and for 6 months after completing treatment; this inclusion is necessary because the treatment in this study may be significantly teratogenic
-
STEP 1 REGISTRATION: The patient or a legally authorized representative must provide study-specific informed consent prior to study entry and, for patients treated in the United States (U.S.), authorization permitting release of personal health information
-
STEP 2 REGISTRATION: Histopathologically proven diagnosis of glioblastoma (or gliosarcoma as a subtype of glioblastoma) confirmed by central pathology review
-
STEP 2 REGISTRATION: MGMT promoter with methylation confirmed by central pathology review (See Section 10 for details). Note: Patients with tissue that is insufficient or inadequate for analysis, fails MGMT testing, or has indeterminate or unmethylated MGMT promoter are excluded. Patients with unmethylated MGMT may be considered for enrollment on NRG-BN007
-
STEP 2 REGISTRATION: IDH mutation testing by at least one method (such as immunohistochemistry for IDH1 R132H) must be performed as part of standard of care and no mutation must be found (i.e IDH wildtype). (If a mutation is identified then the patient will be ineligible and must be registered as ineligible at Step 2.)
-
STEP 2 REGISTRATION: History/physical examination within 28 days prior to Step 2 registration
-
STEP 2 REGISTRATION: Karnofsky performance status (KPS) >= 70 within 28 days prior to Step 2 registration
-
STEP 2 REGISTRATION: Neurologic function assessment within 28 days prior to Step 2 registration
-
STEP 2 REGISTRATION: Age 18-70 years
-
STEP 2 REGISTRATION: Hemoglobin >= 10 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin (Hgb) >= 10.0 g/dl is acceptable)
-
STEP 2 REGISTRATION: Leukocytes >= 2,000/mm^3
-
STEP 2 REGISTRATION: Absolute neutrophil count >= 1,500/mm^3
-
STEP 2 REGISTRATION: Platelets >= 100,000/mm^3
-
STEP 2 REGISTRATION: Total bilirubin =< 1.5 x institutional/lab upper limit of normal (ULN)
-
STEP 2 REGISTRATION: Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) =< 2.5 x ULN
-
STEP 2 REGISTRATION: Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 x ULN
-
STEP 2 REGISTRATION: Serum creatinine =< 1.5 x ULN OR creatinine clearance (CrCl) >= 50 mL/min (if using the Cockcroft-Gault formula
-
STEP 2 REGISTRATION: For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Note: Known positive test for hepatitis B virus surface antigen (HBV sAg) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy. Patients who are immune to hepatitis B (anti-hepatitis B surface antibody positive) are eligible (e.g. patients immunized against hepatitis B)
-
STEP 2 REGISTRATION: For patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Note: Known positive test for hepatitis C virus ribonucleic acid (HCV ribonucleic acid [RNA]) indicating acute or chronic infection would make the patient ineligible unless the viral load becomes undetectable on suppressive therapy
-
STEP 2 REGISTRATION: Known human immunodeficiency virus (HIV) infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months prior to step 2 registration are eligible for this trial. Testing is not required for entry into protocol
-
STEP 2 REGISTRATION: Negative serum or urine pregnancy test (in persons of childbearing potential) within 7 days prior to Step 2 registration
-
Childbearing potential is defined as any person who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal
Exclusion Criteria:
-
STEP 2 REGISTRATION: Prior therapy for tumor except for resection. For example, prior chemotherapy, immunotherapy, or targeted therapy for GBM or lower grade glioma is disallowed (including but not limited to temozolomide, lomustine, bevacizumab, any viral therapy, ipilimumab or other CTLA-4 antibody, PD-1 antibody, CD-137 agonist, CD40 antibody, PDL-1 or 2 antibody, vaccine therapy, polio or similar viral injection as treatment for the tumor, and/or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways) as is prior Laser interstitial thermal therapy (LITT), Gliadel wafer, radiotherapy, radiosurgery, vaccine or other immunotherapy, brachytherapy, or convection enhanced delivery
-
Note: 5-aminolevulinic acid (ALA)-mediated fluorescent guided resection (FGR) photodynamic therapy (PDT) or fluorescein administered prior to/during surgery to aid resection is not exclusionary and is not considered a chemotherapy or intracerebral agent
-
STEP 2 REGISTRATION: Current or planned treatment with any other investigational agents for the study cancer
-
STEP 2 REGISTRATION: Definitive clinical or radiologic evidence of metastatic disease outside the brain
-
STEP 2 REGISTRATION: Prior invasive malignancy (except non-melanomatous skin cancer, cervical cancer in situ and melanoma in situ) unless disease free for a minimum of 2 years
-
STEP 2 REGISTRATION: Prior radiotherapy to the head or neck that would result in overlap of radiation therapy fields
-
STEP 2 REGISTRATION: Pregnancy and individuals unwilling to discontinue nursing due to the potential teratogenic effects and potential risk for adverse events in nursing infants
-
STEP 2 REGISTRATION: History of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or lomustine
-
STEP 2 REGISTRATION: History of pulmonary fibrosis
-
STEP 2 REGISTRATION: Uncontrolled intercurrent illness including, but not limited to:
-
Ongoing or active infection requiring IV antibiotics, IV antiviral, or IV antifungal treatment
-
Symptomatic congestive heart failure, defined as New York Heart Association Functional Classification III/IV (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification)
-
Unstable angina pectoris within 6 months prior to Step 2 registration
-
Uncontrolled cardiac arrhythmia
-
Psychiatric illness/social situations that would limit compliance with study requirements
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | University of Arkansas for Medical Sciences | Little Rock | Arkansas | United States | 72205 |
2 | Kaiser Permanente-Anaheim | Anaheim | California | United States | 92806 |
3 | Sutter Auburn Faith Hospital | Auburn | California | United States | 95602 |
4 | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn | California | United States | 95603 |
5 | Alta Bates Summit Medical Center-Herrick Campus | Berkeley | California | United States | 94704 |
6 | John Muir Medical Center-Concord Campus | Concord | California | United States | 94520 |
7 | Kaiser Permanente Los Angeles Medical Center | Los Angeles | California | United States | 90027 |
8 | Kaiser Permanente-Ontario | Ontario | California | United States | 91761 |
9 | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California | United States | 95661 |
10 | Sutter Roseville Medical Center | Roseville | California | United States | 95661 |
11 | Sutter Medical Center Sacramento | Sacramento | California | United States | 95816 |
12 | John Muir Medical Center-Walnut Creek | Walnut Creek | California | United States | 94598 |
13 | Rocky Mountain Cancer Centers-Penrose | Colorado Springs | Colorado | United States | 80907 |
14 | Littleton Adventist Hospital | Littleton | Colorado | United States | 80122 |
15 | Parker Adventist Hospital | Parker | Colorado | United States | 80138 |
16 | Rush - Copley Medical Center | Aurora | Illinois | United States | 60504 |
17 | Centralia Oncology Clinic | Centralia | Illinois | United States | 62801 |
18 | Carle on Vermilion | Danville | Illinois | United States | 61832 |
19 | Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | United States | 62526 |
20 | Decatur Memorial Hospital | Decatur | Illinois | United States | 62526 |
21 | Carle Physician Group-Effingham | Effingham | Illinois | United States | 62401 |
22 | Crossroads Cancer Center | Effingham | Illinois | United States | 62401 |
23 | Carle Physician Group-Mattoon/Charleston | Mattoon | Illinois | United States | 61938 |
24 | Cancer Care Center of O'Fallon | O'Fallon | Illinois | United States | 62269 |
25 | Southern Illinois University School of Medicine | Springfield | Illinois | United States | 62702 |
26 | Springfield Clinic | Springfield | Illinois | United States | 62702 |
27 | Memorial Medical Center | Springfield | Illinois | United States | 62781 |
28 | Carle Cancer Center | Urbana | Illinois | United States | 61801 |
29 | The Carle Foundation Hospital | Urbana | Illinois | United States | 61801 |
30 | Mary Greeley Medical Center | Ames | Iowa | United States | 50010 |
31 | McFarland Clinic PC - Ames | Ames | Iowa | United States | 50010 |
32 | University of Kansas Cancer Center | Kansas City | Kansas | United States | 66160 |
33 | University of Kansas Hospital-Indian Creek Campus | Overland Park | Kansas | United States | 66211 |
34 | University of Kansas Hospital-Westwood Cancer Center | Westwood | Kansas | United States | 66205 |
35 | Lafayette Family Cancer Center-EMMC | Brewer | Maine | United States | 04412 |
36 | University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | United States | 21201 |
37 | Saint Joseph Mercy Hospital | Ann Arbor | Michigan | United States | 48106 |
38 | Saint Joseph Mercy Brighton | Brighton | Michigan | United States | 48114 |
39 | Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan | United States | 48114 |
40 | Saint Joseph Mercy Canton | Canton | Michigan | United States | 48188 |
41 | Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan | United States | 48188 |
42 | Saint Joseph Mercy Chelsea | Chelsea | Michigan | United States | 48118 |
43 | Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan | United States | 48118 |
44 | Helen DeVos Children's Hospital at Spectrum Health | Grand Rapids | Michigan | United States | 49503 |
45 | Mercy Health Saint Mary's | Grand Rapids | Michigan | United States | 49503 |
46 | Spectrum Health at Butterworth Campus | Grand Rapids | Michigan | United States | 49503 |
47 | Bronson Methodist Hospital | Kalamazoo | Michigan | United States | 49007 |
48 | West Michigan Cancer Center | Kalamazoo | Michigan | United States | 49007 |
49 | Borgess Medical Center | Kalamazoo | Michigan | United States | 49048 |
50 | Trinity Health Saint Mary Mercy Livonia Hospital | Livonia | Michigan | United States | 48154 |
51 | Metro Health Hospital | Wyoming | Michigan | United States | 49519 |
52 | Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus | Ypsilanti | Michigan | United States | 48197 |
53 | Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | United States | 56601 |
54 | Minnesota Oncology - Burnsville | Burnsville | Minnesota | United States | 55337 |
55 | Fairview Southdale Hospital | Edina | Minnesota | United States | 55435 |
56 | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota | United States | 55109 |
57 | Saint John's Hospital - Healtheast | Maplewood | Minnesota | United States | 55109 |
58 | Abbott-Northwestern Hospital | Minneapolis | Minnesota | United States | 55407 |
59 | Hennepin County Medical Center | Minneapolis | Minnesota | United States | 55415 |
60 | Health Partners Inc | Minneapolis | Minnesota | United States | 55454 |
61 | Regions Hospital | Saint Paul | Minnesota | United States | 55101 |
62 | Lakeview Hospital | Stillwater | Minnesota | United States | 55082 |
63 | Saint Francis Medical Center | Cape Girardeau | Missouri | United States | 63703 |
64 | Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri | United States | 63141 |
65 | Parkland Health Center - Farmington | Farmington | Missouri | United States | 63640 |
66 | Research Medical Center | Kansas City | Missouri | United States | 64132 |
67 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
68 | Siteman Cancer Center-South County | Saint Louis | Missouri | United States | 63129 |
69 | Missouri Baptist Medical Center | Saint Louis | Missouri | United States | 63131 |
70 | Siteman Cancer Center at Christian Hospital | Saint Louis | Missouri | United States | 63136 |
71 | Mercy Hospital Saint Louis | Saint Louis | Missouri | United States | 63141 |
72 | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri | United States | 63376 |
73 | Sainte Genevieve County Memorial Hospital | Sainte Genevieve | Missouri | United States | 63670 |
74 | Missouri Baptist Sullivan Hospital | Sullivan | Missouri | United States | 63080 |
75 | Missouri Baptist Outpatient Center-Sunset Hills | Sunset Hills | Missouri | United States | 63127 |
76 | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | United States | 03756 |
77 | Saint Barnabas Medical Center | Livingston | New Jersey | United States | 07039 |
78 | Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | United States | 08903 |
79 | University of New Mexico Cancer Center | Albuquerque | New Mexico | United States | 87102 |
80 | NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center | New York | New York | United States | 10032 |
81 | Sanford Broadway Medical Center | Fargo | North Dakota | United States | 58122 |
82 | Sanford Roger Maris Cancer Center | Fargo | North Dakota | United States | 58122 |
83 | MetroHealth Medical Center | Cleveland | Ohio | United States | 44109 |
84 | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | United States | 73104 |
85 | Legacy Mount Hood Medical Center | Gresham | Oregon | United States | 97030 |
86 | Providence Newberg Medical Center | Newberg | Oregon | United States | 97132 |
87 | Legacy Good Samaritan Hospital and Medical Center | Portland | Oregon | United States | 97210 |
88 | Providence Saint Vincent Medical Center | Portland | Oregon | United States | 97225 |
89 | Kaiser Permanente Northwest | Portland | Oregon | United States | 97227 |
90 | Legacy Meridian Park Hospital | Tualatin | Oregon | United States | 97062 |
91 | Lehigh Valley Hospital-Cedar Crest | Allentown | Pennsylvania | United States | 18103 |
92 | Geisinger Medical Center | Danville | Pennsylvania | United States | 17822 |
93 | Reading Hospital | West Reading | Pennsylvania | United States | 19611 |
94 | Sanford Cancer Center Oncology Clinic | Sioux Falls | South Dakota | United States | 57104 |
95 | Avera Cancer Institute | Sioux Falls | South Dakota | United States | 57105 |
96 | Sanford USD Medical Center - Sioux Falls | Sioux Falls | South Dakota | United States | 57117-5134 |
97 | University of Vermont Medical Center | Burlington | Vermont | United States | 05401 |
98 | University of Vermont and State Agricultural College | Burlington | Vermont | United States | 05405 |
99 | Virginia Mason Medical Center | Seattle | Washington | United States | 98101 |
100 | Legacy Cancer Institute Medical Oncology and Day Treatment | Vancouver | Washington | United States | 98684 |
101 | Legacy Salmon Creek Hospital | Vancouver | Washington | United States | 98686 |
102 | Aurora Cancer Care-Southern Lakes VLCC | Burlington | Wisconsin | United States | 53105 |
103 | Aurora Health Care Germantown Health Center | Germantown | Wisconsin | United States | 53022 |
104 | Aurora Cancer Care-Grafton | Grafton | Wisconsin | United States | 53024 |
105 | Aurora BayCare Medical Center | Green Bay | Wisconsin | United States | 54311 |
106 | Aurora Cancer Care-Kenosha South | Kenosha | Wisconsin | United States | 53142 |
107 | Gundersen Lutheran Medical Center | La Crosse | Wisconsin | United States | 54601 |
108 | Aurora Cancer Care-Milwaukee | Milwaukee | Wisconsin | United States | 53209 |
109 | Aurora Saint Luke's Medical Center | Milwaukee | Wisconsin | United States | 53215 |
110 | Aurora Sinai Medical Center | Milwaukee | Wisconsin | United States | 53233 |
111 | ProHealth D N Greenwald Center | Mukwonago | Wisconsin | United States | 53149 |
112 | Cancer Center of Western Wisconsin | New Richmond | Wisconsin | United States | 54017 |
113 | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin | United States | 53066 |
114 | Vince Lombardi Cancer Clinic - Oshkosh | Oshkosh | Wisconsin | United States | 54904 |
115 | Aurora Cancer Care-Racine | Racine | Wisconsin | United States | 53406 |
116 | Vince Lombardi Cancer Clinic-Sheboygan | Sheboygan | Wisconsin | United States | 53081 |
117 | Aurora Medical Center in Summit | Summit | Wisconsin | United States | 53066 |
118 | UW Cancer Center at ProHealth Care | Waukesha | Wisconsin | United States | 53188 |
119 | Aurora Cancer Care-Milwaukee West | Wauwatosa | Wisconsin | United States | 53226 |
120 | Aurora West Allis Medical Center | West Allis | Wisconsin | United States | 53227 |
Sponsors and Collaborators
- NRG Oncology
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Fabio M Iwamoto, NRG Oncology
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- NRG-BN011
- NCI-2021-10331
- NRG-BN011
- NRG-BN011
- U10CA180868